Shan Fu
Managing Partner, Co-CEO, and CEO of Asia Pacific @ Vivo Capital
Chaoyang, China
Shan Fu is a Series A investor at Vivo Capital in Chaoyang focused on Biotechnology and Pharmaceutical. Shan Fu is based out of Chaoyang, Liaoning and is the Managing Partner, Co-CEO, and CEO of Asia Pacific of Vivo Capital. Shan previously worked at Blackstone as a Senior Managing Director in the Private Equity group and the Chief Representative of Blackstone’s Beijing Office. Shan Fu attended the Peking University in Beijing, China.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 83%
Last updated:
For AI agents: llms.txt
Industries Shan Fu invests in
Stages Shan Fu invests in
Countries Shan Fu invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (50%)
- Pharmaceutical 3 (50%)
- Product Research 2 (33%)
- Sales 1 (17%)
- Medical 1 (17%)
Stage
- Series A 3 (50%)
- Series B 1 (17%)
- Series C 1 (17%)
- Funding Round 1 (17%)
Country
- China 4 (67%)
- United States 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Immunocan
|
Immunocan focuses on the development of fully human antibody animals, artificial chromosome carriers with independent intellectual property rights, focusing on tumor treatment, and developing antibody therapeutic drugs. | $36.8M / Series A / May 13, 2026 | |
Oricell Therapeutics
|
OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy. | $110M / Venture - Series Unknown / Apr 09, 2026 | |
Chentai New Materials
|
Chentai New Materials integrates the R&D, design, manufacturing, and sales of high-performance composite ceramics. It Specializes in the innovation and creation of medical high-performance ceramic products. | $13.7M / Series A / Dec 16, 2024 | |
Visen Pharmaceuticals
|
Visen Pharmaceuticals is a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China. | $150M / Series B / Jan 08, 2021 | |
Provivi
|
Provivi is developing biopesticides for agriculture, commercial, household, and public health pest management. It has a world-class team of founders, scientists, and advisors with significant experience in biotechnology (including biocatalysis), the fine chemicals industry, and, in particular, the agchem industry. It pursues disruptiveopportunities enabled by breakthrough biological processes for making supply-limited products that are efficacious, safe, and environmentally benign.Provivi was founded in 2013 based on biocatalysis technology developed at the California Institute of Technology (Caltech) which has since become a licensor, shareholder, and research collaborator. It is based in Santa Monica, California. | $45.5M / Series C / Dec 22, 2020 | |
|
Visen Pharmaceuticals
|
Visen Pharmaceuticals is a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China. | $40M / Series A / Nov 13, 2018 |
Co-Investors
About Vivo Capital
The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists,entrepreneurs, operating executives, and industry experts. The firm operates as a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.
Vivo Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Gaurav Aggarwal
Managing Director
|
|||
Michael Chang
Managing Partner
|
|||
|
Shan Fu
Managing Partner, Co-CEO, and CEO of Asia Pacific
|
|||
Chloe Zhang
Principal
|
|||
Edgar G. Engleman
Co - Founder & Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Shan Fu invest in?
Shan Fu invests primarily in Biotechnology, Pharmaceutical and Product Research startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Shan Fu?
Public channels for Shan Fu include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Shan Fu last invest?
The most recent investment recorded for Shan Fu closed in May 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
